November 18, 2026
Health news, explained with evidence
LIVE
Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia

New Ranking Highlights Top Players in China's Expanding Biopharmaceutical Sector

❤️ Conditions & Care 2 min read 👁 7

A newly published index evaluates China's leading publicly traded drug developers, pointing to distinct strategies that have driven major companies to multibillion-dollar valuations amid global geopolitical shifts.

New Ranking Highlights Top Players in China's Expanding Biopharmaceutical Sector❤️Conditions & Care

Photo: statnews.com

Key points

  • BeOne Medicines and Jiangsu Hengrui Pharmaceuticals top the newly published China’s Biotech Powerhouse 25 ranking.
  • The index evaluates firms using equally weighted metrics of market capitalization and revenue.
  • Geopolitical tensions and proposed trade policies in Washington continue to influence international biopharma partnerships.

A newly released index from STAT and the risk intelligence platform WireScreen has mapped the landscape of China's rapidly growing pharmaceutical sector. Titled China’s Biotech Powerhouse 25, the ranking evaluates publicly traded firms based equally on market value and revenue to capture how diverse corporate strategies are shaping the global market for new medicines.

Taking the top spot is BeOne Medicines—previously known as BeiGene—which was established in 2010 with a strategy to bridge Eastern and Western markets and develop a worldwide sales infrastructure. Securing the second position is Jiangsu Hengrui Pharmaceuticals, an enterprise with roots as a state-owned generics manufacturer that has transitioned into a key partner for Western pharmaceutical companies seeking to license novel treatments. Both organizations currently hold valuations approaching $50 billion.

The evaluation framework focuses exclusively on Chinese companies whose primary mission is the discovery of innovative therapies for human conditions, omitting contract research organizations and pure-play generic manufacturers. As political discussions in Washington continue regarding potential restrictions on cross-border biotechnology investments, industry leaders emphasize that clinical efficacy and commercial success will ultimately determine the long-term trajectory of these emerging global enterprises.

What to know: The quarterly index tracks the volatile fortunes of China's leading drug developers through shifting market conditions and international trade policies. Readers evaluating global health trends or pharmaceutical investments should consult qualified financial and medical professionals before making personal decisions.

Source statnews.com — statnews.com/2026/11/16/beone-hengrui-top-list-of-chinas-most-power… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.